Tracking a kidney Drug's Real-Life impact
NCT ID NCT02925221
Summary
This study observed over 500 Canadian adults with an inherited kidney disease (ADPKD) who were already prescribed the drug tolvaptan (JINARC™). Its purpose was to see how the drug affected patients' quality of life, pain, and need for treatments like dialysis in a real-world setting. Researchers tracked health outcomes and patient-reported experiences over time without changing their treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Edmonton, Alberta, Canada
-
Study site
London, Ontario, Canada
-
Study site
Ottawa, Ontario, Canada
-
Study site
Toronto, Ontario, Canada
-
Study site
Montreal, Quebec, Canada
-
Study site
Québec, Quebec, Canada
Conditions
Explore the condition pages connected to this study.